Drug intelligence / Profile preview

xiuyisheng

Development stage: Preclinical
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Xiuyisheng is a probiotic intervention being investigated in a randomized controlled trial for its potential to improve intestinal microbiota and metabolites in patients with coronary heart disease after coronary artery bypass graft (CABG) surgery. Probiotics are live microorganisms that, when administered in adequate amounts, are intended to confer a health benefit on the host, primarily by modulating the composition and function of the gut microbiome.

Beyond the preview

Go deeper on xiuyisheng.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xiuyisheng.

Explore the full profile